08 August 2023 | Tuesday | News
Image Source : Public Domain
The agreement further builds upon the strategic collaboration the companies announced in April 2023.
Under the terms of the agreements, DualityBio will receive upfront payments, additional development, regulatory and commercial milestone payments, and single-digit to low-double digit tiered royalties on net sales of DB-1305. BioNTech will hold commercial rights globally (excluding Mainland China, Hong Kong Special Administrative Region and Macau Special Administrative Region), while DualityBio will retain commercial rights for Mainland China, Hong Kong Special Administrative Region and Macau Special Administrative Region.